Kura Oncology, Inc. announced the expansion of its leadership team with three promotions: Mollie Leoni, M.D., to Senior Vice President, Clinical Development, Pete De Spain to Senior Vice President, Investor Relations and Corporate Communications, and Tom Doyle to Senior Vice President, Finance and Accounting. Mr. Doyle will also assume the role of Kura's Principal Accounting Officer from Marc Grasso, M.D., who will be stepping down as the Company's Chief Business Officer, principal accounting officer and principal financial officer, effective February 4, 2022, to pursue opportunities closer to his family. Dr. Grasso will serve in an advisory capacity during the transition.

Mollie Leoni, M.D., joined Kura as Vice President, Clinical Development in February 2020 with extensive drug development experience focused in oncology and orphan diseases. Dr. Leoni has held positions of increasing responsibility within the pharmaceutical industry. Most recently, she served as the Executive Director of Medical Science for Kyowa Kirin, serving as the clinical lead for several oncology programs, including mogamulizumab, which resulted in the successful international registration in cutaneous T-cell lymphoma.

Pete De Spain joined Kura as Vice President, Investor Relations and Corporate Communications in October 2017, bringing more than two decades of biopharma-focused investor relations and corporate communications experience. Before joining Kura, Mr. De Spain served as Vice President of Investor Relations and Corporate Communications at MEI Pharma. Tom Doyle joined Kura as Vice President, Finance in June 2021 with more than 20 years of experience in the biopharma industry, leading finance teams from early stage through commercialization.

Most recently, he was Vice President of Finance at Zogenix, supporting the clinical trials and launch of multiple therapies. Troy E. Wilson, Ph.D., J.D., the Company's President and Chief Executive Officer, as the Company's principal financial officer, each effective as of February 7, 2022.